At the news
? NEUTRALIMPACT 2/10 144 filed Nov 9, 2026 at 16:03 ET
Richard Daniell, Executive VP European Commercial at Teva, filed a Form 144 notice of intent to sell 25,000 ordinary shares with an approximate market value of $1,072,789. The sale is tied to a stock option exercise and compensation, with the proposed sale date of November 9, 2026. This is a routine insider sale by a senior executive, not the CEO or CFO, and represents a small fraction of the company's $48.7B market cap.
- Insider Richard Daniell (Executive VP European Commercial) filed Form 144 to sell 25,000 ordinary shares
- Approximate sale value: $1,072,789.40 based on indicative market price of $42.911576 per share
- Sale is related to a stock option exercise and compensation
- Proposed sale date: November 9, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access